Published in Lab Law Weekly, June 27th, 2008
Aczone(R) Gel 5% is indicated in the United States and Canada for the treatment of acne vulgaris in patients 12 years and older. In two randomized, double-blind, vehicle controlled clinical studies involving approximately 3,000 patients, Aczone(R) Gel 5% achieved a statistically significant reduction in the number of acne lesions and a better success rate relative to vehicle use...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.